Get started

Pharmaceuticals

Biogen trend line to watchBiogen today reported a huge earning beat, but disappointing guidance for the rest of the year. When you crunch the numbers, the midpoint of Biogen's guidance range for 2H 2020 came in slightly below Street consensus for both earnings and revenues. Biogen has a reasonable, but not great valuation, with forward PEG of 3.78 and forward PSG of 1.27. It's currently in the lower half (26th percentile) of its three-year valuation range in terms of forward P/S and forward P/E. Biogen pays no dividend, and as a result the stock is more volatile than a dividend-paying stock would be. Sentiment on Biogen improved quite a bit today. There have been no analyst upgrades yet, but options traders moved from net-bearish to net-bullish positioning for the short term, and from net-bearish to net-neutral positioning for the long term. We're coming up on the strong season for pharmaceutical stocks in August. Biogen has only one phase 2 clinical trial result due in the second half of 2020 for its multiple sclerosis drug, but there are five results due in the first half of 2021, including a phase 3. These could prove to be major catalysts for the stock over the next year. For the near term, watch for a possible trend line break as a sign that the stock will move higher.
NASDAQ:BIIB
by ChristopherCarrollSmith
ABBV buy the dip ahead of pharma seasonAbbvie's volume has slackened somewhat after its recent triangle breakout, and it has broken its steep upward trendline. We may see a small correction late this month as Abbvie pulls back toward triangle top. However, if healthcare and pharmaceutical sector earnings continue to deliver this month (as they have so far), then Abbvie should get some buying volume along with the rest of the sector. And then in August, a period of seasonal pharmaceutical strength begins. In The Stock Traders' Almanac, Jeffrey Hirsch makes an extensive study of seasonal stock market performance by sectors. His third-best-performing seasonal trade by average 10-year return (16.8%) is to go long biotech from early August to early March. I believe that's because this is the busy season for FDA drug application reviews. The pharma sector does have an unusual level of political risk this year. Democrats have traditionally been hard on the pharma sector, and they look poised this year for a sweep. If the polls remain strongly blue, then we might see pharma underperform this year. That said, I think a lot of the political risk is already priced in. Whereas most of the stocks I look at are at the very top of their 3-year valuation range in terms of forward earnings and sales, pharmaceutical companies like Abbvie and Merck are trading in the bottom quartile of their 3-year valuation range. With forward PEG ratio around 2, forward PSG ratio around 0.5, and a whopping 5% dividend, Abbvie looks really attractively valued. I've been doing a lot of deal-hunting lately, and this is one of the only stocks I've seen with both a strong growth story and a valuation I really like. The analysts and options traders like it too; Abbvie has a 9.9/10 Equity Starmine Summary Score, and near-dated options positions are heavily skewed toward calls.
NYSE:ABBVLong
by ChristopherCarrollSmith
1
Vanda Pharmaceuticals! Earnings 40% Trade!!FA: Earings release- the last earnings where the estimate was higher than 0.05 per share it led to the stock rallying by 40%- unless, the earings surprise is a negative one; we can expect a rally from Vanda Pharmaceuticals. TA: Currently been trading in a limited channel- lack of momentum could lead to a dump if earnings estimate is negative or perhaps mean no rally even if the earnings estimate is positive. Watch out for the resistance, it is unlikely to take it out in these market conditions. -Megalodon Whales (Rahim) Enjoyed Charting this for you all,Please SHARE/LIKE/COMMENT and you are welcome to give your feedback or post your own charts below :) NASDAQ:VNDA FWB:VM4
NASDAQ:VNDALong
by BoSukas
2
EQ Watch for Resistance Breakout. Bullish FridayEQ reached top mover status as a gainer one day and a loser the following day. Thursday, EQ was up +1.49% pre-market. I predict stock moves at a steady pace toward $24 price target. EQ is a mall biotech company researching Alzheimer's medicine. Healthcare is our third-largest sector ($6.2 T). Financials ($7.53 T) ranks second and information technology ($9.58 T) first. Please always do your own research. This is not advice. I'm here to learn. Thoughts?
NASDAQ:EQLong
by abreubarbara
1
$MRNA WatchYet another potentially profitable play regarding the Covid-19 pandemic is $MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy in level is at $61-$63 and because of its heavy reliance on the performance of its vaccine to remain profitable I am keeping a tight stop loss. Anything over a 10% drop presents to much risk to feasibly call it worthwhile.
NASDAQ:MRNALong
by Helios_Capital_Investment
VXRT was a top quarterly gainer, rising +376.19%. Expect UptrendVaxart (VXRT, $8) was one of top quarterly gainers, jumping +376.19% to $8 per share. Tickeron A.I.dvisor analyzed 174 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 155 of them (89.09%) charted an Uptrend while 19 of them (10.91%) trended down. Tickeron A.I.dvisor found 135 similar cases when VXRT's price went up 15% within three months. In 83 out of those 135 cases, VXRT's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for VXRT are 61%. VXRT in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on June 30, 2020 This price move signals that VXRT may fall back below the higher band and head toward the middle band. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 37 of 42 cases where VXRT's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 88%.
NASDAQ:VXRTShort
by AlTorress
GLENMARK 01 JULY 2020GLENMARK 01 JULY 2020 SHORT-SELL 2/3 LOT OF GLENMARK @ 430 Dear traders kindly follow our signals for maximum profits, our signals are based on analytics, algorithms, mathematical derivatives. Always be a responsible trader, kindly trade only when you have maximum opportunity in the market with minimum risk and with keynotes like data,analysis and proper strategies. Kindly message me for profit making signals and trades. Dear traders kindly follow our signals for maximum profits, our signals are based on analytics, algorithms, mathematical derivatives. Always be a responsible trader, kindly trade only when you have maximum opportunity in the market with minimum risk and with keynotes like data,analysis and proper strategies. Kindly message me for profit making signals and trades.
NSE:GLENMARKShort
by krishnakanth_kk
1
NKTR was a top gainer, rising +40.26%. Expect Uptrend reversalNektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended down.My A.I.dvisor found 426 similar cases when NKTR's price went up 15% within three months. In 218 out of those 426 cases, NKTR's price went down during the following month. Based on these historical data, my A.I. thinks the odds of an Uptrend reversal for NKTR are 51%.
NASDAQ:NKTRLong
by tickeronAI
1
VRTX - UP and Up and UPHi traders, I have picked another market for today´s analysis. Our best shot for today can be VRTX (we just have to wait for the entry bar). It´s a pharmaceutical company that increased the price of its stock during the Coronavirus crisis. If we compare the price with the SPY market and take the correlation into the consideration we can see that VRTX has more power to the upside than the whole Stock Market (SPY). Correlation - negative or positive - is an important part of portfolio management. If you are LONG in 100 markets that correlates closely to the SPY, it´s almost the same as opening one big position in the SPY market. Be careful! Good trading. Jakub FINEIGHT
AMEX:SPYLong
by Fineight
Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again. But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in. Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NYSE:MRKLong
by ChristopherCarrollSmith
3
BMY at volume support with strong fundamentalsBristol Myers-Squibb got another FDA approval yesterday to expand the label for its immunotherapy drug Opdivo. The approval isn't a huge deal, but it would have been an upward catalyst on a normal stock market day. BMY remains a highly rated stock by analysts, at just 10 forward P/E, 1.17 PEG, and 3% dividend yield. One drawback of BMY is that it has a -1.5% ESP prediction from Zacks, which means its slightly more likely than average to miss its next earnings forecast. I also think we're likely to see some negative sentiment on pharmaceuticals as the Democrats show strength at the polls. My trading plan for BMY is to buy some here, and then triple my position at the $51 volume support node.
NYSE:BMYLong
by ChristopherCarrollSmith